Tag Archives: Karuna Therapeutics

William Blair Reiterates Their Buy Rating on Karuna Therapeutics (KRTX)

William Blair analyst Myles Minter reiterated a Buy rating on Karuna Therapeutics (KRTX – Research Report) on August 4. The company’s shares closed last Monday at $85.95. According to TipRanks.com, Minter is a 4-star analyst with an average return of

William Blair Reiterates a Buy Rating on Karuna Therapeutics (KRTX)

In a report issued on July 28, Myles Minter from William Blair reiterated a Buy rating on Karuna Therapeutics (KRTX – Research Report). The company’s shares closed last Friday at $81.99. According to TipRanks.com, Minter is a 4-star analyst with

Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (NASDAQ: KRTX), Nabriva (NASDAQ: NBRV) and Zynex (NASDAQ: ZYXI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Karuna Therapeutics (KRTX – Research Report), Nabriva (NBRV – Research Report) and Zynex (ZYXI – Research Report). Karuna Therapeutics (KRTX) In a report released today,

Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson initiated coverage with a Buy rating on Karuna Therapeutics (KRTX – Research Report) today and set a price target of $125.00. The company’s shares closed last Monday at $86.17. According to TipRanks.com, Olson is ranked 0

Mizuho Securities Sticks to Their Buy Rating for Karuna Therapeutics (KRTX)

Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Karuna Therapeutics (KRTX – Research Report) today and set a price target of $120.00. The company’s shares closed last Monday at $71.35. According to TipRanks.com, Divan is a 1-star analyst

Wedbush Sticks to Their Buy Rating for Karuna Therapeutics (KRTX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Karuna Therapeutics (KRTX – Research Report) today and set a price target of $38.00. The company’s shares closed last Monday at $17.25. According to TipRanks.com, Moussatos has currently no stars on